Full-Time

Head of Research and Development and Medical Finance

Alexion

Posted on 5/22/2025

Deadline 6/1/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$209.5k - $314.3k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Senior, Expert

Boston, MA, USA

The role requires in-person work a minimum of three days per week from the office, indicating a hybrid work model.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Business Strategy
Financial Modeling
Requirements
  • Strong business partnering skills and experience
  • Bachelor’s degree in finance or accounting
  • Minimum of 10 years of experience in finance, accounting or related business area
  • Minimum of 5 years of experience within the Pharma industry
  • Prior experience of supporting an R&D function
  • Experience in a leadership role interacting with senior management. Ability to drive accountability at the right level.
  • Excellent communication and presentation skills, demonstrated strategic influencing skills
  • Strong business knowledge and acuity
  • Demonstrated people leadership, coaching and/or mentoring skills
  • Proven ability to perform in an environment that emphasizes teamwork
Responsibilities
  • Drive financial robustness, productivity, and associated metrics into the key decision-making processes, including rESPC/rLSPC, and be a key member of the rDRC as well as influencing the portfolio prioritization exercises
  • Manage the budget to support science, drug development, and regional/global medical activities
  • Partner with the Alexion R&D organization across the whole spectrum of drug discovery & research, early and late-stage clinical development, and post-approval medical activities
  • Work with the R&D leadership team to deliver system, process, and organization change, including driving robust and controlled clinical development cost management and determination and allocation of internal resources
  • Lead and develop a team of finance professionals, attracting and retaining talent
  • Be an active member of the Alexion R&D LT, Alexion Finance LT, Global R&D finance leadership team and Global Finance Senior Management Team
  • Ensure data accuracy across all reports and analytics provided to senior leaders (actuals and forecasts)
  • Design and maintain a long-term finance strategy for the business area aligned to the organization’s overall business strategy. Contribute to strategy development for the business area by shaping strategies and developing business and operational plans
  • Challenge, influence, and improve strategies, tactics and plans
  • Oversee the development of financial mechanisms in line with corporate objectives to ensure the achievement of long-term business goals
  • Partner the business in driving R&D productivities initiatives
  • Lead the finance function for Research and Development and Medical in a manner that maximizes contribution to the achievement of business objectives, profitability, and return on investment. Joint accountability with the business for the accuracy of forecasts and leveraging sound understanding of the business model and financial drivers to challenge and influence the key cost drivers
  • Drive a technology enabled strategy, including leveraging AI and use of sophisticated models, reports, and forecasts to challenge and strengthen decision-making processes across R&D.
  • Optimize key relationships with organizations to take full advantage of efficiencies and meet compliance obligations.
  • In partnership with the R&D and Medical Leaders, manage the Business Unit P&L
  • Lead finance and cross-functional teams and drive initiatives leading to increase business improvement
  • Through best practice stakeholder management techniques, explore needs with internal customers and external suppliers and utilize this information to improve business results leveraging significant commercial and business acumen
  • Lead the finance elements of change programs and projects in own area of the business, working with the business to develop and prioritize delivery of the company’s finance strategy for the area
  • Ensure that tactical leadership decisions are enforced for the business to achieve its objectives
  • Work in partnership with the Business and Specialist Finance colleagues to ensure that an environment of continuous professional development is created and individual and team performance is managed effectively
  • Coach and deliver effective performance management to direct and indirect reports creating a supportive work environment where everyone has the opportunity to fulfill their potential
  • Lead Finance role in communicating governance and compliance standards and statutory regulations to non-specialists in a way that is understandable and relevant and relays the risk of commercial decisions effectively
  • Lead insightful and proactive risk management processes to ensure the organization’s regulations, rules and process are adhered to; highlighting areas of concern
Desired Qualifications
  • Demonstrated ability as an agent of change in a dynamic work environment
  • CPA
  • MBA

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases and collaborating with the scientific community to improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's AI partnerships enhance drug discovery and protein folding efficiency.
  • The new Rockville cell therapy facility represents significant investment in future growth.
  • Strategic partnerships, like with Danaher, advance precision medicine diagnostics.

What critics are saying

  • Integration challenges may arise from AstraZeneca's stake in Niox Group.
  • Geopolitical risks could impact the CSPC partnership due to China's regulatory environment.
  • Ethical scrutiny may delay AI solutions like MapDiff in drug discovery.

What makes AstraZeneca unique

  • AstraZeneca focuses on three main therapy areas: Oncology, Cardiovascular, and Respiratory.
  • The company invests heavily in R&D to create innovative prescription medicines.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Devdiscourse
Jun 18th, 2025
AstraZeneca's Stake in Niox Group: A Strategic Partnership | Headlines

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move signals strategic collaboration opportunities between the two companies, potentially aligning their interests in the pharmaceutical industry and expanding their influence in the sector.

InfBusiness
Jun 17th, 2025
Scientists present AI solution for protein folding

Scientists from the University of Sheffield, in partnership with AstraZeneca, have developed an artificial intelligence system called MapDiff, which allows for more efficient creation of proteins with a giventhree-dimensional structure and biological functions.

Cision
Jun 13th, 2025
Astrazeneca Enters Into Collaboration With Cspc

AstraZeneca enters into collaboration with CSPC

Cision
Jun 6th, 2025
Fixed-Duration Calquence Approved In Eu For 1L Cll

Fixed-duration Calquence approved in EU for 1L CLL

Business Weekly
Jun 5th, 2025
Sortera Bio secures ÂŁ7.5m pre-seed funding

Sortera Bio, a Cambridge biotech, secured a ÂŁ7.5m pre-seed round led by Cambridge Innovation Capital, with AstraZeneca and BioNTech participating. The funding will enhance Sortera's Deep Screening platform, which uses AI for drug discovery. Co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, Sortera aims to deliver precision biologics. The technology was developed at the MRC Laboratory of Molecular Biology with AstraZeneca's support.

INACTIVE